Latest Blueprint Medicines News & Updates

See the latest news and media coverage for Blueprint Medicines. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Blueprint Medicines

Global biopharmaceutical company

blueprintmedicines.com
Headquarters
Cambridge, United States
Founded year
2011
Company type
Public company
Number of employees
700–1,000
Industry
Pharmaceuticals

Last updated

Latest news about Blueprint Medicines

In short: Blueprint Medicines was acquired by Sanofi in a deal valued at approximately $9.1 billion, following strong growth of its drug Ayvakit.

Company announcements

Blueprint Medicines

Blueprint Medicines announces AYVAKIT data at EHA and EAACI

Data from PIONEER, PATHFINDER, and EXPLORER trials reinforce sustained efficacy and safety in systemic mastocytosis treatment. Presentations include oral and flash talks.

Unlock all announcements with a

Media coverage

Morningstar

Blueprint Medicines, a Sanofi Company, Announces Four-Year PIONEER Data Showing Sustained Benefit and Long-Term Safety of AYVAKIT® (avapritinib) in Indolent Systemic Mastocytosis

CAMBRIDGE, Mass., Feb. 28, 2026 /PRNewswire/ -- Blueprint Medicines, a Sanofi company, today announced AYVAKIT® (avapritinib) data showing clinically meaningful outcomes and a well-tolerated long-term...

Unlock all articles with a

Never miss news about Blueprint Medicines

Track Blueprint Medicines and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Trending companies

Discover what's making headlines across other trending companies.